EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15 + Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development

Xuqing Shi iD, Hangqi Liu, Jianru Sun, Xiaoding Liu, Xinping Jv, Longyun Chen, Yuhan Zhang, Hui Zhang, Xudong Xing, Ruiyu Li, Xinyi Ke, Jun Wang und 12 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202520029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xuqing Shi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, State Key Laboratory of Common Mechanism Research for Major Diseases, Peking Union Medical College Hospital, Chinese Academy…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Fibroblasts, Cell Adhesion Molecules. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital's Funds for Health Improvement and Research (CFH), National High Level Hospital Clinical Research Funding, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive and desmoplastic tumor microenvironment (TME) that limits the efficacy of immunotherapy. However, the evolution of this immunosuppressive TME and the underlying mechanisms remain incompletely understood. Here, we construct a dynamic single‐cell atlas spanning uninvolved adjacent pancreatic tissue (UNIN), intraductal papillary mucinous neoplasm (IPMN), and PDAC. We confirm the stepwise establishment of an immunosuppressive milieu, accompanied by the emergence of LRRC15 + fibroblasts as determinants. Functional assays further identify tumor‐derived LAMB3 as a regulator of LRRC15 + fibroblast differentiation. Mechanistically, LAMB3 promotes FOSL2‐dependent transcriptional activation of LRRC15 through the ITGB1/FAK/MAPK signaling axis, ultimately suppressing T cell cytotoxicity. Orthotopic models reveal that LAMB3 overexpression increases the LRRC15 positive area and impairs T cell cytotoxicity, whereas FAK inhibition partially reverses these effects. In parallel, LAMB3 knockdown reduces the LRRC15 positive area and improves the efficacy of PD‐1 blockade. Moreover, glycolytic reprogramming in PDAC ductal cells upregulates LAMB3 expression and correlates with increased LRRC15 + fibroblast enrichment. Clinically, co‐enrichment of LAMB3 + PDAC ductal cells and LRRC15 + fibroblasts is associated with inferior overall survival. Collectively, our findings define a dynamic ductal‐fibroblast‐immune multicellular axis underlying PDAC pathogenesis and provide insights into potential therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsFibroblastsCell Adhesion MoleculesHumansAnimalsTumor MicroenvironmentKalininMice

Stichwörter der Autor:innen

cancer‐associated fibroblastscellular crosstalklamininleucine‐rich repeat‐containing 15pancreatic ductal adenocarcinomas

Substanzen

KalininCell Adhesion Molecules

Autor:innen und Institutionen

  • Department of Pathology, State Key Laboratory of Common Mechanism Research for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Biomedical Pioneering Innovation Center (BIOPIC), Peking-Tsinghua Center for Life Sciences, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Pekin…
  • Peking University Beijing-Tianjin-Hebei Biomedical Pioneering Innovation Center, Tianjin, China.

ORCID-Profile: Xuqing Shi, Zhiyong Liang

Förderung

  • Capital's Funds for Health Improvement and Research (CFH)
  • National High Level Hospital Clinical Research Funding
  • National Key Research and Development Program of China
  • National Science Fund for Distinguished Young Scholars
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Shi, X., Liu, H., Sun, J., Liu, X., Jv, X., Chen, L., Zhang, Y., Zhang, H., Xing, X., Li, R., Ke, X., Wang, J., Yin, X., Liu, B., Liu, Q., Wang, Y., Lu, J., Liu, S., Pang, J., …, & Liang, Z. (2026). Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15 + Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Advanced Science. https://doi.org/10.1002/advs.202520029

Vancouver

Shi X, Liu H, Sun J, Liu X, Jv X, Chen L, et al. Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15 + Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Advanced Science. 2026. doi:10.1002/advs.202520029

BibTeX
@article{Shi2026,
  author = {Shi, Xuqing and Liu, Hangqi and Sun, Jianru and Liu, Xiaoding and Jv, Xinping and Chen, Longyun and Zhang, Yuhan and Zhang, Hui and Xing, Xudong and Li, Ruiyu and Ke, Xinyi and Wang, Jun and Yin, Xianglin and Liu, Bohan and Liu, Qixian and Wang, Yuan and Lu, Junliang and Liu, Shiyi and Pang, Junyi and Cai, Yumeng and Dai, Menghua and Bai, Fan and Wu, Huanwen and Liang, Zhiyong},
  title = {Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15 + Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202520029}
}
Kostenlos starten →